The Oxford Science Park

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

OrganOx appoints John Liddicoat M.D. as Non-Executive Director to the Board

01 Dec 2022

OrganOx, a world leader in normothermic machine perfusion (NMP), today announces the appointment of Dr. John Liddicoat M.D. as Non-Executive Director to the Board. "I am delighted to be joining OrganOx in the wake of FDA approval. This Company is at the start of its commercial journey in the US and based on my experience of ground breaking medical devices, I can see tremendous potential for this technology to transform the liver transplant... Read more

Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

14 Nov 2022

Effort aligns MD Anderson’s drug development expertise with Exscientia’s AI-driven patient-first precision medicine and drug discovery platforms OXFORD, England & HOUSTON, Texas--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and... Read more

Next step in expansion of TOSP with detailed planning application submitted for Plot 27

14 Nov 2022

Next step in expansion of TOSP with detailed planning application submitted for Plot 27 New R&D building part of >500,000 sq ft expansion plan as the Park innovation ecosystem grows Oxford, UK, November 14 2022 –The Oxford Science Park (TOSP), one of Europe's leading locations for science and technology companies, is delighted to announce the next step in its development plan with the submission of a detailed planning application for a new... Read more

Jérôme Marzinski appointed as Chief Executive Officer

07 Nov 2022

Seasoned medtech leader with a proven track record in scaling companies Oxford, UK – 7 November 2022 – OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its ultrasound-based drug delivery platform, announces that it has appointed Jérôme Marzinski as its Chief Executive Officer with immediate effect. Jérôme is a seasoned medtech leader, having held a variety of senior roles over a... Read more

OxSonics presents preclinical data demonstrating SonoTran® enhanced the delivery and efficacy of an oncolytic virus in a murine bladder cancel model

25 Oct 2022

OxSonics presents preclinical data demonstrating SonoTran® enhanced the delivery and efficacy of an oncolytic virus in a murine bladder cancel model Data presented at the International Oncolytic Virus Conference (IOVC) from a collaboration with Turnstone Biologics. Oxford, UK – 25 October 2022 – OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its ultrasound-based drug delivery... Read more

News